Kenneth Bartizal

Nessuna posizione attualmente

72 anni

Health Technology

Consumer Services

Profilo

Kenneth F.
Bartizal worked as a Research Scientist at Pfizer Inc. from 1986 to 1988.
He was a Faculty Member at Truman State University from 1983 to 1986 and at Kirksville College of Osteopathic Medicine, Inc. from 1983 to 1986.
He served as Executive Director & Head-Infectious Diseases at Merck & Co., Inc. from 2007 to 2007 and as Chief Development Officer at Trius Therapeutics, Inc. from 2007 to 2014.
He also worked as Principal at Pfizer Central Research and as Chief Development Officer at Cidara Therapeutics, Inc. Dr. Bartizal received his undergraduate, graduate, and doctorate degrees from the University of Notre Dame.

Precedenti posizioni note di Kenneth Bartizal

Società	Posizione	Fine
Trius Therapeutics, Inc. Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.	Corporate Officer/Principal	-
MERCK & CO., INC.	Direttore/Membro del Consiglio	01/04/2007
PFIZER, INC.	Corporate Officer/Principal	01/01/1988
Kirksville College of Osteopathic Medicine, Inc.	Corporate Officer/Principal	-
Truman State University	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Kenneth Bartizal

Formazione di Kenneth Bartizal

University of Notre Dame

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Kenneth Bartizal

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	3
PFIZER, INC.	Health Technology
MERCK & CO., INC.	Health Technology
CIDARA THERAPEUTICS, INC.	Health Technology

Aziende private	1
Trius Therapeutics, Inc. Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.	Health Technology